We present a rare opportunity to see experts from across the pharmaceutical and CRO industries sharing perspectives on new technology integration in the field of bioanalysis.
MetaboQuan-r for bile acids in human serum: a rapid, targeted UPLC-MS/MS method for metabolomic research studies
Bile acids are an important class of biological molecules that are generated in the liver and play a central role in various biological functions, including cholesterol homeostasis. Quantitative analysis for research of bile acids using LC-MS is complicated by the presence of many isomeric compounds.Historically, this has meant that throughput has been compromised in order to separate these isomeric compounds. Here we demonstrate how these compounds can be separated, without compromising throughput, using Waters® CORTECS UPLC Technology combined with negative mode electrospray ionization mass spectrometry. This application note is also part of a MetaboQuan-R method package.
Developing bioanalytical LC–MS/MS methods for biotherapeutics and biomarkers: an interview with William Mylott
In this expert interview, William Mylott discusses developing bioanalytical LC–MS/MS methods for biotherapeutics and biomarkers.
Opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers
Learn more about opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers in this article from Future Science OA.
This infographic presents key results from the large molecule quantification by LC–MS survey.
In this interview, Jun Qu (University at Buffalo; NY, USA) describes his current research focuses, including the technologies he is currently developing. Jun goes on to discuss the challenges involved in implementing sensitive quantifications of biotherapeutics using LC–MS and speculates on the future of the technology.
In this interview, Lawrence Goodwin (KCAS, KS, USA) explains his passion for tandem technology, the portfolio of services that KCAS offers and the advantages and disadvantages of their key technologies chromatography and mass spectrometry.
Poster: an immunoaffinity capture/UPLC-MS/MS method for multiplexed quantitation of two highly homologous antibodies in human serum
Monoclonal antibody (mAb) based biotherapeutics have emerged as a dominant class of approved medicines during the past decade in both market share and variety of target diseases. Ligand binding assays (LBAs), such as enzyme-linked immunosorbent assays (ELISA), have been the gold standard for the bioanalysis of mAbs in support of non-clinical and clinical trials. While conventional LBAs provide highly sensitive and specific detection for the quantitation of mAbs, combining an LBA with liquid chromatography tandem mass spectrometry (LC-MS/MS) detection offers additional orthogonal dimensions of selectivity/specificity, extending the assay utility to a multiplexed format otherwise not achievable by LBA alone.
Available to view on demand.
In this free panel discussion, our experts will provide insights into their own research with large molecules including the challenges they have had to overcome, key trends they have seen and their future outlook of the development of this field. There is also an opportunity for your own questions to be answered in the live Q&A.
To date, almost all protein LC-MS/MS based bioanalysis has involved the use of trypsin to cleave biopharmaceuticals into manageable peptides for quantitation. In some cases, where trypsin does not generate useful peptide sequences, a different cleavage agent is required. Glu-C is an enzyme that is frequently used for protein characterisation, and cuts proteins on the C-terminal side of the aspartic and glutamic acid residues. These two molecules are acidic amino acids, whereas the ubiquitous trypsin cleaves at the basic residues (lysine and arginine), therefore making this an orthogonal cleavage enzyme.